U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327840) titled 'Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)' on Dec. 25, 2025.
Brief Summary: This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Study Start Date: Oct. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Lipoprotein Disorder
Intervention:
DRUG: Kylo-11 or matched placebo
Administered subcutaneously
Recruitment Status: RECRUITING
Sponsor: Kylonova (Xiamen) Biopharma co., LTD.
Disclaimer: Curated by HT Syndication....